Literature DB >> 20711589

[TNM classification of breast cancer: changes and comments on the 7th edition].

H-P Sinn1, B Helmchen, C H Wittekind.   

Abstract

The 7th edition of the TNM classification includes only minor changes in the main TNM categories for breast cancer. Only ductal and lobular carcinoma in situ (DCIS, LCIS), and isolated Paget's disease of the nipple are classified as pTis, but not precursor lesions such as atypical ductal or lobular hyperplasia (ADH, ALH). AJCC emphasizes that microscopic measurement is the most accurate and preferred method to determine pT in small invasive cancers and stresses the importance of strict adherence to criteria for T4 cancers. For better distinction from micrometastases in regional lymph nodes, small clusters of cells not greater than 0.2 mm, or nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single histologic lymph node cross section are classified as isolated tumour cells (pN0(i+)). The pN classification has otherwise remained unchanged. In the setting of patients having received neoadjuvant therapy, ypT1-ypT3 is based on the total extent of viable tumour cells, irrespective of tumour regression. Stage I breast tumours have been subdivided into Stage IA and Stage IB; Stage IB includes small tumours (TI) with lymph node micrometastases (N1mi). These changes and clarifications will contribute to maintaining the clinical and prognostic relevance of TNM in breast cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20711589     DOI: 10.1007/s00292-010-1307-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  19 in total

1.  Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases.

Authors:  G Vlastos; M E Jean; A N Mirza; N Q Mirza; H M Kuerer; F C Ames; K K Hunt; M I Ross; T A Buchholz; A U Buzdar; S E Singletary
Journal:  Ann Surg Oncol       Date:  2001-06       Impact factor: 5.344

2.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Authors:  Lisa A Carey; Richard Metzger; E Claire Dees; Frances Collichio; Carolyn I Sartor; David W Ollila; Nancy Klauber-DeMore; Jan Halle; Lynda Sawyer; Dominic T Moore; Mark L Graham
Journal:  J Natl Cancer Inst       Date:  2005-08-03       Impact factor: 13.506

3.  Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification.

Authors:  Uwe Güth; Dorothy Jane Huang; Andreas Schötzau; Stephan Dirnhofer; Edward Wight; Gad Singer
Journal:  Breast       Date:  2009-12-16       Impact factor: 4.380

4.  INTERNATIONAL Union Against Cancer. Clinical stage classification for malignant tumours of the breast.

Authors: 
Journal:  Br J Surg       Date:  1959-11       Impact factor: 6.939

5.  INTERNATIONAL Union against Cancer. Clinical stage classification. Malignant tumours of the breast. 1960-1964.

Authors: 
Journal:  Br J Radiol       Date:  1959-12       Impact factor: 3.039

6.  The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis.

Authors:  Steven L Chen; Francesca M Hoehne; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

Review 7.  Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.

Authors:  Sunati Sahoo; Susan C Lester
Journal:  Arch Pathol Lab Med       Date:  2009-04       Impact factor: 5.534

8.  Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training.

Authors:  Roderick R Turner; Donald L Weaver; Gabor Cserni; Susan C Lester; Karen Hirsch; David A Elashoff; Patrick L Fitzgibbons; Giuseppe Viale; Giovanni Mazzarol; Julio A Ibarra; Stuart J Schnitt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

9.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?

Authors:  William F Anderson; Kenneth C Chu; Shine Chang
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

10.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

View more
  17 in total

1.  Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.

Authors:  Chang-Li Wang; Yue Li; Dong-Sheng Yue; Lian-Min Zhang; Zhen-Fa Zhang; Bing-Sheng Sun
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.

Authors:  Xiang Lu; Yingying Zhao; Caiping Chen; Chao Han; Li Xue; Dan Xing; Ou Huang; Min Tao
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

Review 3.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Jeffrey I Campbell; Christina Yau; Polina Krass; Dan Moore; Lisa A Carey; Alfred Au; David Chhieng; Dilip Giri; Chad Livasy; Carolyn Mies; Joseph Rabban; Venetia R Sarode; Baljit Singh; Laura Esserman; Yunn-Yi Chen
Journal:  Breast Cancer Res Treat       Date:  2017-06-02       Impact factor: 4.872

5.  Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer.

Authors:  Sylvia Timme; Martin Sillem; Peter Bronsert; Lioudmila Bogatyreva; Dieter Hauschke; Axel Zur Hausen; Martin Werner; Elmar Stickeler
Journal:  Breast Care (Basel)       Date:  2017-08-02       Impact factor: 2.860

6.  The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.

Authors:  Mengyu Pang; Fenglian Zhao; Pengyue Yu; Xiaohua Zhang; Hexin Xiao; Wang Qiang; Hongquan Zhu; Liyan Zhao
Journal:  Gland Surg       Date:  2021-04

7.  Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

Authors:  Ning Lv; Xiaoming Xie; Qidong Ge; Suxia Lin; Xi Wang; Yanan Kong; Hongliu Shi; Xinhua Xie; Weidong Wei
Journal:  Diagn Pathol       Date:  2011-12-02       Impact factor: 2.644

8.  Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.

Authors:  Masaya Tamura; Isao Matsumoto; Daisuke Saito; Shuhei Yoshida; Munehisa Takata; Hirofumi Takemura
Journal:  World J Surg Oncol       Date:  2016-11-25       Impact factor: 2.754

9.  Clinical significance of MSKCC nomogram on guiding the application of touch imprint cytology and frozen section in intraoperative assessment of breast sentinel lymph nodes.

Authors:  Lisha Sun; Guanglei Chen; Yizhen Zhou; Lei Zhang; Zining Jin; Weiguang Liu; Guangping Wu; Feng Jin; Kai Li; Bo Chen
Journal:  Oncotarget       Date:  2017-04-27

10.  CD44+/CD24- phenotype predicts a poor prognosis in triple-negative breast cancer.

Authors:  Hui Wang; Li Wang; Ying Song; Shuhuai Wang; Xu Huang; Qijia Xuan; Xinmei Kang; Qingyuan Zhang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.